• SELECT SITE CURRENCY
Select a currency for use throughout the site
Global Hepatitis C Drugs Market 2011-2015
Infiniti Research Limited, May 2012, Pages: 37
TechNavio’s analysts forecast the Global Hepatitis C Drugs market to grow at a CAGR of 28 percent over the period 2011–2015. One of the key factors contributing to this market growth is the increasing prevalence of hepatitis C infection. The Global Hepatitis C Drugs market has also been witnessing the shift of treatments from multiple drug therapy to single drug therapy. However, the virus developing resistance to the drugs could pose a challenge to the growth of this market.
TechNavio’s report, the Global Hepatitis C Drugs Market 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hepatitis C Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include GlaxoSmithKline plc, Merck & Co. Inc., Roche Holding Ltd., and Vertex Pharmaceuticals Ltd.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
01. Executive Summary
03. Market Coverage
04. Market Landscape
05. Geographical Segmentation
06. Key Leading Countries
07. Rate of Incidence and Prevalence
08. Vendor Landscape
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Key Vendor Analysis
15.1 Roche Holding Ltd.
15.2 Merck & Co. Inc.
15.3 GlaxoSmithKline plc
15.4 Vertex Pharmaceuticals Ltd.
16. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Hepatitis C Drugs Market 2011–2015 (US$ billion)
Exhibit 2: Global Hepatitis C Drugs Market Segmentation by Therapy 2011
Exhibit 3: Global Hepatitis C Drugs Market by Geographical Segmentation 2011
Exhibit 4: Hepatitis C Infection by Source 2011
Exhibit 5: Global Hepatitis C Drugs Market by Vendor Segmentation 2011
TechNavio Announces the Publication of its Report – Global Hepatitis C Drugs Market 2011–2015
TechNavio today launched its report Global Hepatitis C Drugs Market 2011–2015 based on an in-depth study covering the Americas and the EMEA and APAC regions. The report aims to aid decision makers’ understanding of the present and the future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; “Vendors are partnering with each other to share their competencies in order to develop more efficient drugs and penetrate the hitherto unexplored market. Hence, vendors are forming strategic alliances with each other to market their manufactured drugs in the unexplored regions and to thereby increase their market share in the Global Hepatitis C Drugs market.”
According to the report, novel and newly-introduced drugs such as telaprevir and boceprevir, which are more effective than drugs for multiple drug therapy in the treatment of the hepatitis C infection, have helped to increase the growth of the Global Hepatitis C Drugs market. In addition, several new drugs which are being developed for use in single drug therapy are expected to be launched in the market by 2014. Moreover, these drugs are expected to provide cost-effective treatment for the hepatitis C infection, thereby increasing the growth of the market.
Further, the report also discusses that the unavailability of drugs to meet the market demand adversely affects the growth of the Global Hepatitis C Drugs market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
Roche Holding, Merck & Co, GlaxoSmithKline plc, Vertex Pharmaceuticals